{"id":"afatinib-osimertinib-carboplatin-and-pemetrexed","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Rash"},{"rate":"10-30%","effect":"Anemia"},{"rate":"10-30%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Anorexia"},{"rate":"5-20%","effect":"Weight loss"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Afatinib and Osimertinib specifically target the EGFR tyrosine kinase domain, leading to the inhibition of tumor cell proliferation. Carboplatin forms platinum-DNA adducts, which interfere with DNA replication and transcription, ultimately leading to cell death. Pemetrexed inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, which are essential for DNA synthesis and repair.","oneSentence":"Afatinib and Osimertinib are irreversible tyrosine kinase inhibitors targeting the epidermal growth factor receptor (EGFR), while Carboplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, and Pemetrexed is an antifolate drug that inhibits thymidylate synthase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:20:14.738Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, Squamous non-small cell lung cancer, Non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858R mutation"},{"name":"Malignant pleural mesothelioma"}]},"trialDetails":[{"nctId":"NCT05298176","phase":"PHASE2","title":"Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2022-01-04","conditions":"Non-Small Cell Lung Cancer","enrollment":5},{"nctId":"NCT04115410","phase":"","title":"PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2020-07-01","conditions":"Carcinoma, Non-Small-Cell Lung, Immune-Related Adverse Events","enrollment":4724}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Afatinib, Osimertinib, Carboplatin and Pemetrexed","genericName":"Afatinib, Osimertinib, Carboplatin and Pemetrexed","companyName":"Amsterdam UMC, location VUmc","companyId":"amsterdam-umc-location-vumc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Afatinib and Osimertinib are irreversible tyrosine kinase inhibitors targeting the epidermal growth factor receptor (EGFR), while Carboplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, and Pemetrexed is an antifolate drug that inhibits thymidylate synthase. Used for Non-small cell lung cancer, Squamous non-small cell lung cancer, Non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858R mutation, Malignant pleural mesothelioma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}